CohBar, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Pinchas Cohen Dean,
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1455 Adams Drive Menlo Park CA United States of America 94025
- IPO Date
- Dec 15, 2017
- CIK
- 0001522602
- Website
- cohbar.com
- Similar Companies
- Business
- CohBar, Inc. (NASDAQ: CWBR) operates as a clinical-stage biotechnology company focused on the research, development, and commercialization of mitochondria-based therapeutics (MBTs) derived from novel peptides encoded in the mitochondrial genome; these include Mitochondrial Derived Peptides (MDPs) such as CB4211, an analogue of MOTS-c in Phase 1a/1b trials targeting non-alcoholic steatohepatitis (NASH), obesity, and related metabolic conditions through improved insulin sensitivity and liver health; CB5138 analogs in preclinical development for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases by addressing underlying fibrotic mechanisms; and additional MDP analogs explored for applications in cancer, type 2 diabetes, acute kidney injury, cardiovascular diseases, and acute respiratory distress syndrome. The company serves patients with chronic and age-related diseases across segments including metabolic disorders, fibrosis, oncology, and neurodegeneration, with operations historically centered in the United States. Founded in 2007 by pioneers in aging research including Dr. Pinchas Cohen, Dr. Nir Barzilai, Dr. John Amatruda, and David Sinclair—stemming from discoveries at the University of Southern California and Albert Einstein College of Medicine—CohBar maintains headquarters in Menlo Park, California, following prior relocations including to Tucson, Arizona. In a major strategic shift, CohBar enters into a definitive merger agreement with Morphogenesis, Inc. in May 2023 to form TuHURA Biosciences, Inc., adopting the partner's late-stage immuno-oncology pipeline featuring the IFx-Hu2.0 personalized cancer vaccine platform and tumor microenvironment modulators designed to overcome resistance to checkpoint inhibitors, supported by a concurrent $15 million private placement financing for clinical advancement through 2024; although the merger terminates in November 2023 due to Nasdaq listing challenges, the company executes a 1-for-30 reverse stock split in 2023 to meet exchange requirements, pauses CB4211 development post-Phase 1b to prioritize resources, and reports ongoing R&D investments including $1.8 million in Q1 2024 alongside a net loss amid persistent funding needs; as of December 2025, CohBar confirms it no longer operates, directing inquiries to specified contacts while its common stock trades over-the-counter.
CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)
COHBAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of CohBar, Inc. - CWBR
CohBar Reports Second Quarter 2023 Financial Results
Shareholder Alert: Ademi LLP investigates whether CohBar, Inc. has obtained a Fair Price in its transaction with Morphogenesis, Inc.
Why Is CohBar (CWBR) Stock Up 130% Today?
CWBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of CohBar, Inc. Is Fair to Shareholders
CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
Cohbar Inc. (CWBR) Upgraded to Strong Buy: What Does It Mean for the Stock?
7 Nasdaq Stocks to Sell Before They Die
CohBar (CWBR) Stock: 1-For-30 Reverse Split Goes Into Effect
CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference
CohBar, Inc. (CWBR) CEO Joe Sarret on Q2 2022 Results - Earnings Call Transcript
CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022
CohBar to Present at the H.C. Wainwright Global Investment Conference
CohBar Inc. (CWBR) CEO Joe Sarret on Q1 2022 Results - Earnings Call Transcript
CohBar to Announce 2022 First Quarter Financial Results and Provide Business Update on May 16, 2022
CohBar, Inc. (CWBR) CEO Joe Sarret on Q4 2021 Results - Earnings Call Transcript
CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022
CohBar to Present at H.C. Wainwright BIOCONNECT Conference
7 of the Best Penny Stocks Under $3 for 2022 to Buy Now